Connect Biopharma Holdings (CNTB) Price & Analysis

Compare

114 Followers

CNTB Stock Chart & Stats

$1.55

$0.04(3.94%)

At close: Jan 08 4:00 PM EST

$1.55

$0.04(3.94%)

Day’s Range― - ―

52-Week Range$0.51 - $2.86

Previous CloseN/A

Volume1.98K

Average Volume (3M)97.97K

Market Cap

$93.61M

Enterprise Value-$16.51M

Total Cash (Recent Filing)$71.77M

Total Debt (Recent Filing)$870.00K

Price to Earnings (P/E)―

Beta0.56

Next Earnings

Mar 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.23

Shares Outstanding55,721,657

10 Day Avg. Volume111,495

30 Day Avg. Volume97,966

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)0.83

Price to Sales (P/S)2.93

P/FCF Ratio-3.13

Enterprise Value/Market Cap-0.18

Enterprise Value/Revenue-8.42

Enterprise Value/Gross Profit-9.29

Enterprise Value/Ebitda0.46

Forecast

1Y Price Target

$7.67

Price Target Upside394.84% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Partnership PotentialCNTB is likely to attract the interest of a much larger partner if the acute data is compelling, which could provide commercial expertise and funding.

Therapeutic DifferentiationRademikibart could ultimately displace Dupixent in the chronic setting due to its differentiation in the acute setting.

Unique Label ClaimCNTB's potential to be the first and only asthma or COPD therapy with an acute exacerbation claim in its label is supported by strong data.

Bears Say

Commercialization ChallengesThe low EU probability of success for rademikibart is attributed to the current model of CNTB self-commercializing in the EU without a partnership.

Connect Biopharma Holdings News

Connect Biopharma initiated with a Buy at BTIG

BTIG initiated coverage of Connect Biopharma (CNTB) with a Buy rating and $10 price target The firm believes...

10d ago

CNTB

Promising Outlook for Connect Biopharma Holdings: Rademikibart’s Potential in Asthma and COPD

Brandon Folkes, an analyst from H.C. Wainwright, reiterated the Buy rating on Connect Biopharma Holdings. The associated price...

6d ago

CNTB

Buy Rating for Connect Biopharma: Promising Clinical Data and Market Potential for Rademikibart

Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Connect Biopharma Holdings and keeping the price...

1M ago

CNTB

Connect Biopharma presents data on rademikibart at ERS Congress

Connect Biopharma (CNTB) Holdings presented data supporting rademikibart, the Company’s investigational, next-generation, potentially best-in-class anti-interleukin-4-receptor alpha antibody, at...

1M ago

CNTB

Connect Biopharma Executives Increase Share Holdings

Connect Biopharma Holdings ( ($CNTB) ) has issued an announcement. Between September 2024 and September 2025, Barry D....

2M ago

CNTB

Connect Biopharma management to meet virtually with Northland

Virtual Meeting to be held on September 23 at 10 am hosted by Northland. Published first on TheFly...

2M ago

CNTB

Connect Biopharma completes termination of ADR program, lists on Nasdaq

Connect Biopharma (CNTB) completed the termination of the Deposit Agreement dated March 18, 2021, as amended, among the...

2M ago

CNTB

Connect Biopharma Advances Clinical Trials and Nasdaq Listing

Connect Biopharma Holdings Ltd. ( ($CNTB) ) has released its Q2 earnings. Here is a breakdown of the...

3M ago

CNTB

Connect Biopharma patners with Ickey Woods, Jovante Woods Foundation

Connect Biopharma (CNTB) and the Jovante Woods Foundation kicked off a collaboration to expand the Foundation’s asthma education...

3M ago

CNTB

Promising Developments and Strategic Moves Justify Buy Rating for Connect Biopharma Holdings

Analyst Brandon Folkes of H.C. Wainwright reiterated a Buy rating on Connect Biopharma Holdings, retaining the price target...

3M ago

CNTB

Connect Biopharma reports Q2 EPS (23c) vs. 27c last year

Reports Q2 revenue $48,000 vs. $24.1M last year. “In the second quarter, we made significant progress across our...

3M ago

CNTB

Connect Biopharma sees cash runway into 2027

Cash, cash equivalents and short-term investments were $71.8 million as of June 30, 2025. Based on its current...

3M ago

CNTB

Connect Biopharma Expands Board, Appoints New Director

Connect Biopharma Holdings ( ($CNTB) ) just unveiled an update. On July 22, 2025, Connect Biopharma Holdings Limited...

4M ago

CNTB

Connect Biopharma announces expansion of board, appoints Schoeneck as director

Connect Biopharma (CNTB) announced the expansion of the size of its Board of Directors from six to seven...

4M ago

CNTB

CNTB FAQ

What was Connect Biopharma Holdings’s price range in the past 12 months?

Connect Biopharma Holdings lowest stock price was $0.51 and its highest was $2.86 in the past 12 months.

What is Connect Biopharma Holdings’s market cap?

Connect Biopharma Holdings’s market cap is $93.61M.

When is Connect Biopharma Holdings’s upcoming earnings report date?

Connect Biopharma Holdings’s upcoming earnings report date is Mar 26, 2026 which is in 136 days.

How were Connect Biopharma Holdings’s earnings last quarter?

Connect Biopharma Holdings released its earnings results on Aug 13, 2025. The company reported -$0.232 earnings per share for the quarter, missing the consensus estimate of -$0.222 by -$0.01.

Is Connect Biopharma Holdings overvalued?

According to Wall Street analysts Connect Biopharma Holdings’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Connect Biopharma Holdings pay dividends?

Connect Biopharma Holdings does not currently pay dividends.

What is Connect Biopharma Holdings’s EPS estimate?

Connect Biopharma Holdings’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Connect Biopharma Holdings have?

Connect Biopharma Holdings has 55,721,657 shares outstanding.

What happened to Connect Biopharma Holdings’s price movement after its last earnings report?

Connect Biopharma Holdings reported an EPS of -$0.232 in its last earnings report, missing expectations of -$0.222. Following the earnings report the stock price went up 3.965%.

Which hedge fund is a major shareholder of Connect Biopharma Holdings?

Currently, no hedge funds are holding shares in CNTB

Connect Biopharma Holdings Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-15.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Connect Biopharma Holdings

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

Connect Biopharma Holdings (CNTB) Earnings & Revenues

Historic Earnings Reports

CNTB Stock 12 Month Forecast

Average Price Target

$7.67

▲(394.84% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Mar<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.71,2.3476923076923075,2.985384615384615,3.623076923076923,4.260769230769231,4.898461538461538,5.536153846153846,6.173846153846154,6.811538461538461,7.449230769230769,8.086923076923076,8.724615384615383,9.362307692307692,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.71,2.168461538461538,2.626923076923077,3.0853846153846156,3.543846153846154,4.002307692307692,4.46076923076923,4.9192307692307695,5.377692307692308,5.836153846153846,6.294615384615384,6.753076923076923,7.211538461538462,{"y":7.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.71,2.04,2.37,2.7,3.0300000000000002,3.3600000000000003,3.69,4.02,4.35,4.68,5.01,5.34,5.67,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.18,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.79,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.6,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.57,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.11,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >